Dynavax Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Decisions with the Full Value Chain Report
This Dynavax Value Chain Analysis shows how the company creates value through its support activities and primary activities in a clear, structured format. The page already includes a real preview of the actual report, so you can see what the analysis looks like before buying. Purchase the full version to get the complete ready-to-use analysis.
Support Activities
Firm Infrastructure
Dynavax's firm infrastructure is built around FDA compliance, cGMP controls, and tight financial reporting for international adjuvant deals. This setup supports disciplined capital use for late-stage trials and commercial execution; in FY2025, that mattered as the Company kept R&D and partner oversight aligned with a regulated biologics platform. Strong governance also helps Dynavax manage cross-border quality and audit demands without slowing decision-making.
Human Resource Management
Dynavax's human resource management centers on hiring niche immunology scientists and a small, high-output sales team to support HEPLISAV-B in the mature U.S. vaccine market. This matters because its 2025 cost base stayed talent-heavy, with R&D and SG&A still the main operating lines, so keeping expert staff in place protects know-how and limits churn in critical roles. The commercial team then focuses on U.S. retail pharmacies and health systems, where even a few strong reps can move meaningful prescription volume.
Technology Development
Dynavax centers Technology Development on its proprietary TLR9 agonist platform, CpG 1018, which supports HEPLISAV-B and gives the Company a reusable adjuvant base. In 2025, the platform's moat widened as Dynavax kept building long-term clinical data and advanced 2 expansion paths: shingles and Tdap candidates. That matters because a stronger adjuvant system can lift vaccine durability and speed follow-on programs without rebuilding the core biology from scratch.
Procurement
In fiscal 2025, Dynavax's procurement focused on high-purity biological inputs and tight control of specialized third-party manufacturers for HEPLISAV-B. Long-term supplier contracts help reduce raw-material shortages and support steadier cost of goods sold, which matters when vaccine supply and quality checks are tied to a small set of qualified vendors.
This function is one reason Dynavax can keep production reliable while limiting disruption risk across a narrow biologics supply chain.
Dynavax Keeps It Lean While Expanding CpG 1018
In FY2025, Dynavax's support activities stayed lean: compliance, finance, and quality systems kept a small biologics base stable, while a niche science team and compact sales force protected HEPLISAV-B execution. Technology work stayed centered on CpG 1018, with 2 expansion paths in shingles and Tdap. Procurement remained tight around specialized third-party manufacturers and qualified inputs.
| FY2025 factor | Data |
|---|---|
| Platform | CpG 1018 |
| Expansion paths | 2 |
| Commercial focus | HEPLISAV-B |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Dynavax's inbound logistics centers on cold-chain delivery of raw materials and vaccine inputs from specialized suppliers to its manufacturing and testing sites. This matters because HEPLISAV-B is a 2-dose adult hepatitis B vaccine, so any delay in temperature-sensitive lots can hit output fast. Tight inventory control also protects high-value CpG 1018 adjuvant supply, helping Dynavax avoid bottlenecks when demand shifts.
Operations
Dynavax's operations center on GMP biological manufacturing and release testing for HEPLISAV-B and CpG 1018 at Emeryville and partner sites, with each lot checked for identity, potency, and safety. HEPLISAV-B's 2-dose, 1-month schedule has driven seroprotection above 90% in pivotal adult trials, so tight batch control matters. In fiscal 2025, this production base supported the company's vaccine supply and adjuvant revenue stream.
Outbound Logistics
Dynavax's outbound logistics centers on HEPLISAV-B, a 2-dose adult hepatitis B vaccine that must reach clinicians and distributors on time so the second dose can be given 1 month after the first. A 3PL cold-chain network helps move vials from warehouses nationwide while limiting spoilage and stockouts.
That coordination supports dependable fill rates and protects sales tied to the full series, which is critical in 2025 as every delayed shipment can break the dosing window and hurt patient completion.
Marketing and Sales
Dynavax's marketing and sales team focuses on healthcare stakeholders, Group Purchasing Organizations, and the Department of Defense, using a targeted field force to win vaccine access. The key message is simple: HEPLISAV-B is a two-dose hepatitis B vaccine given over 1 month, versus the standard three-dose options that take 6 months, which helps raise series completion and supports commercial share.
- Targeted sales coverage
- Two-dose completion advantage
- Works with large buyers
Service
Dynavax's service activity centers on post-commercialization support: medical affairs teams help providers, patient assistance programs improve access, and pharmacovigilance tracks long-term safety after launch. This work matters for immunization committees because real-world safety and use data help sustain adoption of HEPLISAV-B and support clinician trust. In 2025, that service layer helps protect repeat demand by keeping the medical community informed and reducing friction for patients and providers.
Dynavax's HBV Edge: Faster Dosing, Stronger Protection
Dynavax's primary activities in 2025 were commercializing HEPLISAV-B and supplying CpG 1018, so operations, sales, and service all focus on one fast-moving hepatitis B franchise. The 2-dose, 1-month schedule is simpler than 3-dose, 6-month rivals, and pivotal trials showed seroprotection above 90%. That gives Dynavax a clear field edge.
| Primary activity | 2025 fact |
|---|---|
| Operations | HEPLISAV-B and CpG 1018 |
| Sales edge | 2 doses in 1 month |
| Clinical proof | >90% seroprotection |
What You See Is What You Get
Dynavax Reference Sources
This is the actual Dynavax Value Chain Analysis document you'll receive upon purchase – no surprises, just a professional, ready-to-use report. The preview below is taken directly from the full analysis, so what you see is exactly what you get. Once purchased, the complete version is unlocked instantly.
Frequently Asked Questions
Dynavax utilizes a network of third-party logistics providers to manage a strictly controlled cold-chain distribution process. As of 2026, this infrastructure supports the delivery of vaccines across over 10,000 healthcare sites in the United States. This high level of precision ensures the integrity of HEPLISAV-B, which remains a cornerstone of the company's ability to generate more than $200 million in annual product revenue.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.